The Immunopathogenesis and Immunotherapy of Cutaneous T Cell Lymphoma: Pathways and Targets for Immune Restoration and Tumor Eradication

Overview

Journal J Am Acad Dermatol

Specialty Dermatology

Date 2020 Dec 22

PMID 33352267

Citations 15

Authors

Joseph S Durgin

David M Weiner

Maria Wysocka

Alain H Rook

Affiliations

Soon will be listed here.

Abstract

Cutaneous T cell lymphomas (CTCLs) are malignancies of skin-trafficking T cells. Patients with advanced CTCL manifest immune dysfunction that predisposes to infection and suppresses the antitumor immune response. Therapies that stimulate immunity have produced superior progression-free survival compared with conventional chemotherapy, reinforcing the importance of addressing the immune deficient state in the care of patients with CTCL. Recent research has better defined the pathogenesis of these immune deficits, explaining the mechanisms of disease progression and revealing potential therapeutic targets. The features of the malignant cell in mycosis fungoides and Sézary syndrome are now significantly better understood, including the T helper 2 cell phenotype, regulatory T cell cytokine production, immune checkpoint molecule expression, chemokine receptors, and interactions with the microenvironment. The updated model of CTCL immunopathogenesis provides understanding into clinical progression and therapeutic response.

Citing Articles

Cutaneous T-Cell Lymphoma and Microbiota: Etiopathogenesis and Potential New Therapeutic Targets.

Rodriguez Baeza D, Bejarano Antonio L, Gonzalez de Arriba M, Pico-Monllor J, Canueto J, Navarro-Lopez V Dermatol Res Pract. 2024; 2024:9919225.

PMID: 38435536 PMC: 10904680. DOI: 10.1155/2024/9919225.

Integrating artificial intelligence in osteosarcoma prognosis: the prognostic significance of SERPINE2 and CPT1B biomarkers.

Qu H, Jiang J, Zhan X, Liang Y, Guo Q, Liu P Sci Rep. 2024; 14(1):4318.

PMID: 38383657 PMC: 10881519. DOI: 10.1038/s41598-024-54222-6.

Association of Cardiovascular Disease in Patients with Mycosis Fungoides and Sézary Syndrome Compared to a Matched Control Cohort.

Johnson C, Talluru S, Bubic B, Colbert M, Kumar P, Tsai H JID Innov. 2023; 3(6):100219.

PMID: 38116332 PMC: 10730311. DOI: 10.1016/j.xjidi.2023.100219.

What Is New in Cutaneous T Cell Lymphoma?.

Morgenroth S, Roggo A, Pawlik L, Dummer R, Ramelyte E Curr Oncol Rep. 2023; 25(11):1397-1408.

PMID: 37874473 PMC: 10640416. DOI: 10.1007/s11912-023-01464-8.

Role of cytokine in malignant T-cell metabolism and subsequent alternation in T-cell tumor microenvironment.

Yadav M, Uikey B, Rathore S, Gupta P, Kashyap D, Kumar C Front Oncol. 2023; 13:1235711.

PMID: 37746258 PMC: 10513393. DOI: 10.3389/fonc.2023.1235711.

References

Marzec M, Liu X, Wysocka M, Rook A, Odum N, Wasik M . Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells. PLoS One. 2011; 6(9):e24849. PMC: 3174990. DOI: 10.1371/journal.pone.0024849. View

Willerslev-Olsen A, Krejsgaard T, Lindahl L, Bonefeld C, Wasik M, Koralov S . Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma. Toxins (Basel). 2013; 5(8):1402-21. PMC: 3760043. DOI: 10.3390/toxins5081402. View

Wilcox R, Feldman A, Wada D, Yang Z, Comfere N, Dong H . B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 2009; 114(10):2149-58. PMC: 2744574. DOI: 10.1182/blood-2009-04-216671. View

Kopp K, Ralfkiaer U, Gjerdrum L, Helvad R, Pedersen I, Litman T . STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle. 2013; 12(12):1939-47. PMC: 3735708. DOI: 10.4161/cc.24987. View

Dobbeling U, Dummer R, Laine E, Potoczna N, Qin J, Burg G . Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood. 1998; 92(1):252-8. View

Guenova E, Watanabe R, Teague J, DeSimone J, Jiang Y, Dowlatshahi M . TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res. 2013; 19(14):3755-63. PMC: 3715586. DOI: 10.1158/1078-0432.CCR-12-3488. View

Mirvish E, Pomerantz R, Geskin L . Infectious agents in cutaneous T-cell lymphoma. J Am Acad Dermatol. 2010; 64(2):423-31. PMC: 3954537. DOI: 10.1016/j.jaad.2009.11.692. View

Ureshino H, Shindo T, Nishikawa H, Watanabe N, Watanabe E, Satoh N . Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia. Cancer Immunol Res. 2016; 4(8):644-9. DOI: 10.1158/2326-6066.CIR-15-0303. View

Lindahl L, Willerslev-Olsen A, Gjerdrum L, Nielsen P, Blumel E, Rittig A . Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. Blood. 2019; 134(13):1072-1083. PMC: 6764271. DOI: 10.1182/blood.2018888107. View

10.

Wolk K, Mitsui H, Witte K, Gellrich S, Gulati N, Humme D . Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas: role of Th2-mediated biased Th17 function. Clin Cancer Res. 2014; 20(21):5507-16. DOI: 10.1158/1078-0432.CCR-14-0707. View

11.

Yoo E, Cassin M, Lessin S, Rook A . Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity. J Am Acad Dermatol. 2001; 45(2):208-16. DOI: 10.1067/mjd.2001.116345. View

12.

Martinez-Escala M, Posligua A, Wickless H, Rutherford A, Sable K, Rubio-Gonzalez B . Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol. 2018; 78(6):1068-1076. PMC: 5951749. DOI: 10.1016/j.jaad.2017.12.068. View

13.

van Doorn R, van Kester M, Dijkman R, Vermeer M, Mulder A, Szuhai K . Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood. 2008; 113(1):127-36. DOI: 10.1182/blood-2008-04-153031. View

14.

Meech S, Edelson R, Walsh P, Norris D, Duke R . Reversible resistance to apoptosis in cutaneous T cell lymphoma. Ann N Y Acad Sci. 2001; 941:46-58. DOI: 10.1111/j.1749-6632.2001.tb03710.x. View

15.

Di Renzo M, Rubegni P, De Aloe G, Paulesu L, Pasqui A, Andreassi L . Extracorporeal photochemotherapy restores Th1/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma. Immunology. 1997; 92(1):99-103. PMC: 1363987. DOI: 10.1046/j.1365-2567.1997.00325.x. View

16.

Narducci M, Scala E, Bresin A, Caprini E, Picchio M, Remotti D . Skin homing of Sézary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV. Blood. 2005; 107(3):1108-15. DOI: 10.1182/blood-2005-04-1492. View

17.

Olsen E, Rook A, Zic J, Kim Y, Porcu P, Querfeld C . Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol. 2010; 64(2):352-404. DOI: 10.1016/j.jaad.2010.08.037. View

18.

Jariwala N, Benoit B, Kossenkov A, Oetjen L, Whelan T, Cornejo C . TIGIT and Helios Are Highly Expressed on CD4 T Cells in Sézary Syndrome Patients. J Invest Dermatol. 2016; 137(1):257-260. PMC: 5358509. DOI: 10.1016/j.jid.2016.08.016. View

19.

Zhu J . Transcriptional regulation of Th2 cell differentiation. Immunol Cell Biol. 2010; 88(3):244-9. PMC: 3477614. DOI: 10.1038/icb.2009.114. View

20.

Netchiporouk E, Litvinov I, Moreau L, Gilbert M, Sasseville D, Duvic M . Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. Cell Cycle. 2014; 13(21):3331-5. PMC: 4612117. DOI: 10.4161/15384101.2014.965061. View